Die another way: necroptosis as alternative route to cell death

Júlia Aguadé-Gorgorió(University of California, Los Angeles), Beat Bornhäuser(University Children's Hospital Zurich), Caterina Mezzatesta(University Children's Hospital Zurich), Martin Schrappe(University Hospital Schleswig-Holstein), Scott McComb(University of Ottawa), Gunnar Cario, MP Dobay, Jean‐Pierre Bourquin(University Children's Hospital Zurich), Cornelia Eckert(Humboldt-Universität zu Berlin), A von Stackelberg(Royal London Hospital), Martin Stanulla(Leibniz University Hannover)
Klinische Pädiatrie
May 1, 2017
10.1055/s-0037-1602216
Cited by 0

Related Papers

Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
|Journal of Clinical Oncology|2015|1k
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
|The Lancet|1998|964
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95
|Blood|2008|607
Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region
|The Lancet|2002|401
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group
|Blood|2009|347